JP2015514086A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514086A5 JP2015514086A5 JP2015503348A JP2015503348A JP2015514086A5 JP 2015514086 A5 JP2015514086 A5 JP 2015514086A5 JP 2015503348 A JP2015503348 A JP 2015503348A JP 2015503348 A JP2015503348 A JP 2015503348A JP 2015514086 A5 JP2015514086 A5 JP 2015514086A5
- Authority
- JP
- Japan
- Prior art keywords
- hemoglobin
- conjugate according
- peg
- hemoglobin conjugate
- anemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010054147 Hemoglobins Proteins 0.000 claims 30
- 102000001554 Hemoglobins Human genes 0.000 claims 30
- 229920001223 polyethylene glycol Polymers 0.000 claims 9
- 239000002202 Polyethylene glycol Substances 0.000 claims 6
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 6
- 210000000056 organ Anatomy 0.000 claims 5
- 108010025915 Nitrite Reductases Proteins 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 3
- 208000007475 hemolytic anemia Diseases 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 230000035939 shock Effects 0.000 claims 3
- 208000032467 Aplastic anaemia Diseases 0.000 claims 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
- 239000005977 Ethylene Substances 0.000 claims 2
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000025911 acute intestinal ischemia Diseases 0.000 claims 2
- 201000006781 acute vascular insufficiency of intestine Diseases 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 206010000804 Acute hepatic failure Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010002091 Anaesthesia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 206010021074 Hypoplastic anaemia Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010022971 Iron Deficiencies Diseases 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 claims 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 241000097929 Porphyria Species 0.000 claims 1
- 208000010642 Porphyrias Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 201000010789 Spermatic Cord Torsion Diseases 0.000 claims 1
- 206010041660 Splenomegaly Diseases 0.000 claims 1
- 206010043356 Testicular torsion Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 231100000836 acute liver failure Toxicity 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000037005 anaesthesia Effects 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000005980 beta thalassemia Diseases 0.000 claims 1
- 208000022806 beta-thalassemia major Diseases 0.000 claims 1
- RHDWKUYFKXIIOF-OWOJBTEDSA-N bis[(3,6-dibromo-6-hydroxycyclohexa-2,4-dien-1-yl)methyl] (e)-but-2-enedioate Chemical compound OC1(Br)C=CC(Br)=CC1COC(=O)\C=C\C(=O)OCC1C(Br)(O)C=CC(Br)=C1 RHDWKUYFKXIIOF-OWOJBTEDSA-N 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000003633 blood substitute Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 1
- 239000001569 carbon dioxide Substances 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229940045200 cardioprotective agent Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000002316 cosmetic surgery Methods 0.000 claims 1
- 230000002338 cryopreservative effect Effects 0.000 claims 1
- 208000029039 cyanide poisoning Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 238000002059 diagnostic imaging Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 238000013467 fragmentation Methods 0.000 claims 1
- 238000006062 fragmentation reaction Methods 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 230000002949 hemolytic effect Effects 0.000 claims 1
- 201000004108 hypersplenism Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 201000002818 limb ischemia Diseases 0.000 claims 1
- 210000003141 lower extremity Anatomy 0.000 claims 1
- 230000004199 lung function Effects 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000006353 oxyethylene group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 244000144977 poultry Species 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 108010001708 stroma free hemoglobin Proteins 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
- 239000003357 wound healing promoting agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261617639P | 2012-03-29 | 2012-03-29 | |
| US61/617,639 | 2012-03-29 | ||
| PCT/US2013/032694 WO2013148375A1 (en) | 2012-03-29 | 2013-03-15 | Diaspirin crosslinked pegylated hemoglobin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019005963A Division JP6668515B2 (ja) | 2012-03-29 | 2019-01-17 | ジアスピリン架橋ｐｅｇヘモグロビン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015514086A JP2015514086A (ja) | 2015-05-18 |
| JP2015514086A5 true JP2015514086A5 (enExample) | 2016-04-28 |
Family
ID=49261107
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503348A Pending JP2015514086A (ja) | 2012-03-29 | 2013-03-15 | ジアスピリン架橋ｐｅｇヘモグロビン |
| JP2019005963A Expired - Fee Related JP6668515B2 (ja) | 2012-03-29 | 2019-01-17 | ジアスピリン架橋ｐｅｇヘモグロビン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019005963A Expired - Fee Related JP6668515B2 (ja) | 2012-03-29 | 2019-01-17 | ジアスピリン架橋ｐｅｇヘモグロビン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10029001B2 (enExample) |
| EP (1) | EP2830638B1 (enExample) |
| JP (2) | JP2015514086A (enExample) |
| KR (1) | KR102144139B1 (enExample) |
| CN (2) | CN109731098A (enExample) |
| AU (1) | AU2013240141B2 (enExample) |
| CA (1) | CA2908236C (enExample) |
| HK (1) | HK1207560A1 (enExample) |
| MX (1) | MX358785B (enExample) |
| WO (1) | WO2013148375A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912805SA (en) * | 2014-12-19 | 2020-02-27 | Aragon Pharmaceuticals Inc | Process for the preparation of a diarylthiohydantoin compound |
| CN105017515A (zh) * | 2015-07-20 | 2015-11-04 | 湖南华腾制药有限公司 | 聚乙二醇修饰物的制备方法 |
| CN106421805B (zh) * | 2016-09-14 | 2019-06-04 | 中国人民解放军军事医学科学院野战输血研究所 | 一种右旋糖酐交联血红蛋白氧载体及其制备方法与应用 |
| CA3070172A1 (en) | 2017-07-18 | 2019-01-24 | VirTech Bio, Inc. | Blood substitutes comprising hemoglobin and methods of making |
| WO2022184005A1 (en) | 2021-03-01 | 2022-09-09 | Billion King International Limited | Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof |
| CN114146165B (zh) * | 2021-12-02 | 2022-08-12 | 润方（北京）生物医药研究院有限公司 | 一种聚合血红蛋白在制备防治呼吸衰竭药物中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4529719A (en) | 1983-05-04 | 1985-07-16 | Tye Ross W | Modified crosslinked stroma-free tetrameric hemoglobin |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| CA1312009C (en) | 1986-11-10 | 1992-12-29 | Carl W. Rausch | Extra pure semi-synthetic blood substitute |
| US5234903A (en) | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
| US5585484A (en) | 1995-04-19 | 1996-12-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Hemoglobin crosslinkers |
| US6627738B2 (en) | 1995-09-15 | 2003-09-30 | Duke University | No-modified hemoglobins and uses therefor |
| AU2002320628A1 (en) | 2001-07-19 | 2003-03-03 | Albert Einstein College Of Medecine Of Yeshiva University | Size enhanced hemoglobins: surface decoration and crosslinking of the protein with polyoxy akylene glycols |
| US20050164915A1 (en) * | 2002-04-01 | 2005-07-28 | Sangart, Inc. | Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| US20030153491A1 (en) | 2002-01-11 | 2003-08-14 | Winslow Robert M. | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| US7144989B2 (en) | 2002-03-25 | 2006-12-05 | Albert Einstein College Of Medicine Of Yeshiva University | Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof |
| CA2511494A1 (en) | 2002-12-23 | 2004-07-15 | Seetharama A. Acharya | Non-hypertensive polyethylene glycol-modified hemoglobin as oxygen carrier |
| KR100512483B1 (ko) | 2003-05-07 | 2005-09-05 | 선바이오(주) | 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법 |
| AU2005279780B2 (en) * | 2004-08-31 | 2011-02-03 | Sangart, Inc. | Methods to enhance hemodynamic stability using oxygen carrying compositions |
| WO2006096774A2 (en) * | 2005-03-07 | 2006-09-14 | Sangart, Inc. | Composition and methods for delivering carbon monoxide (co) and nitric ozide (no) co to tissue using heme proteins as carriers |
| US8741832B2 (en) | 2005-06-10 | 2014-06-03 | Albert Einstein College Of Medicine Of Yeshiva University | Pegylated albumin and uses thereof |
| US7504377B2 (en) * | 2006-10-23 | 2009-03-17 | Ikor, Inc. | Nitric oxide-blocked cross-linked tetrameric hemoglobin |
| CN102859364A (zh) * | 2010-02-25 | 2013-01-02 | 桑格特公司 | 通过减少反应物比例制备聚乙二醇-血红蛋白缀合物的方法 |
| US20130052232A1 (en) | 2011-08-31 | 2013-02-28 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking |
-
2013
- 2013-03-15 US US14/388,956 patent/US10029001B2/en active Active
- 2013-03-15 JP JP2015503348A patent/JP2015514086A/ja active Pending
- 2013-03-15 CN CN201910069033.4A patent/CN109731098A/zh active Pending
- 2013-03-15 CA CA2908236A patent/CA2908236C/en active Active
- 2013-03-15 EP EP13769757.9A patent/EP2830638B1/en active Active
- 2013-03-15 CN CN201380027621.2A patent/CN104379160A/zh active Pending
- 2013-03-15 HK HK15108131.6A patent/HK1207560A1/xx unknown
- 2013-03-15 MX MX2014011763A patent/MX358785B/es active IP Right Grant
- 2013-03-15 AU AU2013240141A patent/AU2013240141B2/en not_active Ceased
- 2013-03-15 WO PCT/US2013/032694 patent/WO2013148375A1/en not_active Ceased
- 2013-03-15 KR KR1020147030304A patent/KR102144139B1/ko not_active Expired - Fee Related
-
2019
- 2019-01-17 JP JP2019005963A patent/JP6668515B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514718A5 (enExample) | ||
| JP2015514086A5 (enExample) | ||
| US12329822B2 (en) | Antimicrobial tailored chitosan | |
| CN104411807B (zh) | 琥珀酰亚胺活化型硝酰化合物及其用于蛋白质硝酰化的使用方法 | |
| JP2016521258A5 (enExample) | ||
| CN106714820A (zh) | 选择素及icam/vcam肽配体偶联物 | |
| EP3016693A1 (en) | Dissolvable hydrogel compositions for wound management and methods of use | |
| JP6799823B2 (ja) | ポリ（ｌ−アルギニン）セグメント含有ブロック共重合体とポリアニオン性ポリマーのポリイオンコンプレックス | |
| TW200812572A (en) | Polymer conjugate of taxane | |
| JP6668515B2 (ja) | ジアスピリン架橋ｐｅｇヘモグロビン | |
| EP2838550A1 (en) | Polymeric conjugates of c1-inhibitors | |
| US5900402A (en) | Method of reducing side effects associated with administration of oxygen-carrying proteins | |
| JP5657011B2 (ja) | カテコールポリエチレングリコール誘導体と蛋白質またはペプチドの接合体、及びこれの製造方法 | |
| JP2020534840A5 (enExample) | ||
| US20200222548A1 (en) | Synthetic bioconjugates | |
| JP2026040471A (ja) | キトサン－核酸ナノ粒子の可逆的コーティング及びその使用方法 | |
| JP6657070B2 (ja) | ポリアルキレンオキシド吉草酸ヘモグロビン接合体 | |
| CN109963597A (zh) | 聚乙二醇化血管内皮抑制素类似物及其应用 | |
| JP5281358B2 (ja) | 高分子、経上皮吸収促進剤、及び医薬用製剤 | |
| CN102617852A (zh) | 马来酰亚胺-聚谷氨酸-天冬氨酸聚合物和其复合物、及其制备方法和用途 | |
| JP7773169B2 (ja) | ポリオキサゾリン結合アルブミン、人工血漿増量剤及び出血ショックの蘇生液 | |
| Huang et al. | Protective Effect of Mitochondria-Targeted Polydopamine Nanoparticles in Alleviating Hepatic Ischemia-Reperfusion Injury | |
| HK1238155A1 (en) | Selectin and icam/vcam peptide ligand conjugates | |
| HK1219053B (zh) | 聚环氧烷戊酸酯血红蛋白缀合物 |